# OnCo record nct07276399 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07276399/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07276399", "NCT07276399" ;
  schema:name "A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer"@en ;
  schema:alternateName "OrigAMI-5"@en ;
  schema:description "A phase 3 trial of Amivantamab, Pembrolizumab, Carboplatin and Cisplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07276399/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07276399> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-12-03" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .